NASDAQ:KZR
Kezar Life Sciences Inc Stock News
$0.705
-0.0236 (-3.24%)
At Close: May 24, 2024
Kezar Life Sciences to Participate in the Jefferies Virtual Healthcare Conference
07:00am, Thursday, 27'th May 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and
Kezar Life Sciences to Present at BIO CEO & Investor Digital Conference
04:01pm, Wednesday, 10'th Feb 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and
Kezar Life Sciences: Targeting The Immunoproteasome To Treat Autoimmunity
01:00pm, Thursday, 28'th Jan 2021
Kezar is a founder-driven company with deep expertise in proteasome and drug development, and they have a track record of approved medicines. The company's lead asset, KZR-616, is a first-in-class inh
Kezar Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
04:02pm, Thursday, 07'th Jan 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and
Kezar Life Sciences: Keyed In On Autoimmune Therapies
09:01am, Friday, 06'th Nov 2020
Kezar is a young company with two candidates in clinical development. Development programs with broad therapeutic potential.
Kezar Highlights Broad Therapeutic Potential of KZR-616 During ACR Convergence 2020
08:46am, Thursday, 05'th Nov 2020
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and
Kezar Life Sciences (KZR) Investor Presentation - Slideshow
05:46pm, Friday, 11'th Sep 2020
The following slide deck was published by Kezar Life Sciences, Inc. in conjunction with this event..
Kezar Life Sciences: Exploring New Options For Autoimmune Diseases
09:54am, Monday, 07'th Sep 2020
KZR-616 is a new promising first-in-class selective proteasome inhibitor, which might help patients with autoimmune diseases, such as lupus, polymyositis, and dermatomyositis.
What Is The Ownership Structure Like For Kezar Life Sciences, Inc. (NASDAQ:KZR)?
12:59pm, Tuesday, 11'th Aug 2020
Every investor in Kezar Life Sciences, Inc. (NASDAQ:KZR) should be aware of the most powerful shareholder groups...
Is Kezar Life Sciences, Inc.'s (NASDAQ:KZR) Shareholder Ownership Skewed Towards Insiders?
12:53pm, Tuesday, 11'th Aug 2020
Every investor in Kezar Life Sciences, Inc. (NASDAQ:KZR) should be aware of the most powerful shareholder groups...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Flexion Therapeutics
NFL: Dozens of players positive for COVID-19 since training camps open, opt-out deadline looms
12:00am, Thursday, 06'th Aug 2020
NFL: Dozens of players positive for COVID-19 since training camps open, opt-out deadline looms
Kezar Life Sciences Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update
08:01pm, Wednesday, 05'th Aug 2020
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its seco
Kezar Life Sciences to Participate in Two Upcoming Virtual Investor Conferences
08:01pm, Monday, 03'rd Aug 2020
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today anno
Kezar Life Sciences to Participate in Two Upcoming Virtual Investor Conferences
12:00am, Monday, 03'rd Aug 2020
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat
